Please provide your email address to receive an email when new articles are posted on . This installment of Pipeline Pulse focuses on a single cardiovascular risk ...
Findings from a phase 1 trial show that an experimental 'gene silencing' therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%. Findings from a new Cleveland ...
Thirty-year outcomes among participants in the Women's Health Study showed a stepwise increase in major cardiovascular events associated with increasing lipoprotein(a) levels starting around 30-60 ...
Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...
Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower ...
Please note: This product is for research use only. Lipoproteins can be described as supramolecular assemblies that carry water-insoluble lipids in the blood. They also carry apolipoproteins that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results